[Radiation therapy for brain tumors]
- PMID: 15688744
[Radiation therapy for brain tumors]
Abstract
Brain tumors respond differently to treatment with surgery plus radiotherapy or radiotherapy alone, combined with or without chemotherapy, because they are characterized by subtypes with different histologies. Since the development of diagnostic radiology, such as computed tomography (CT) and magnetic resonance imaging (MRI), brain tumors have been easier to demonstrate and can be found at earlier stages than in the conventional situation. Furthermore, highly technical devices and equipment for radiation therapy have been developed and installed for clinical use, especially with multileaf collimator (MLC) and treatment planning systems. In the field of radiotherapy for brain tumors, it has been possible to use more precise treatment planning with conformal radiotherapy, three-dimensional treatment planning, and stereotactic radiotherapy. Dose escalation studies and the modified fractionation schedule of radiotherapy can also be designed by analyzing biological data and applying hypofractionated intensity-modulated radiotherapy (IMRT) to radioresistant tumors such as glioblastoma multiforme and anaplastic astrocytoma. Future investigation may be useful to determine which fraction size is likely to be optimal for these malignant gliomas when highly conformal radiotherapy is used in adjuvant treatment. These technological developments and newly designed radiosensitizing agents will improve local control rates and survival times, thereby enhancing the quality of life in patients suffering from various kinds of brain tumors.
Similar articles
-
Radiotherapy of malignant gliomas: results from conventional treatment methods and the prospects of advanced techniques.Radiol Med. 2004 Jan-Feb;107(1-2):128-35. Radiol Med. 2004. PMID: 15031704 English, Italian.
-
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.Radiother Oncol. 2010 Dec;97(3):377-81. doi: 10.1016/j.radonc.2010.08.020. Epub 2010 Sep 18. Radiother Oncol. 2010. PMID: 20855119
-
[Technologic developments in radiotherapy and stereotactic radiosurgery].Neurochirurgie. 2001 May;47(2-3 Pt 2):260-6. Neurochirurgie. 2001. PMID: 11404704 Review. French.
-
[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].Rofo. 2006 Jun;178(6):627-33. doi: 10.1055/s-2006-926744. Epub 2006 May 15. Rofo. 2006. PMID: 16703499 German.
-
[Chemoradiation for malignant brain tumors].Gan To Kagaku Ryoho. 1997 Nov;24(14):2042-8. Gan To Kagaku Ryoho. 1997. PMID: 9388512 Review. Japanese.
Cited by
-
Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.Neurol Med Chir (Tokyo). 2014;54(4):280-9. doi: 10.2176/nmc.oa2013-0117. Epub 2013 Dec 5. Neurol Med Chir (Tokyo). 2014. PMID: 24305028 Free PMC article.
-
Prediction of Normal Tissue Complication Probability (NTCP) After Radiation Therapy Using Imaging and Molecular Biomarkers and Multivariate Modelling.J Mol Neurosci. 2023 Aug;73(7-8):587-597. doi: 10.1007/s12031-023-02136-9. Epub 2023 Jul 18. J Mol Neurosci. 2023. PMID: 37462853
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical